New drug therapy for squamous carcinoma of the head and neck

Current Opinion in Oncology

Volumn 8, Issue 3, 1996, Pages 221-226

  Murphy, Barbara A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMONAFIDE; ANTIMETABOLITE; CISPLATIN; DOCETAXEL; EDATREXATE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; PIRITREXIM; PODOPHYLLOTOXIN; RETINOIC ACID; RETINOID; SPERGUALIN; TOPOTECAN;

CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 0029996801     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199605000-00009     Document Type: Review

References (61)

1. Armand JP, Couteau C: Chemotherapy in head and neck cancer. Eur J Cancer 1995, 31A:819-822.
2. Dutch DS, Edelstein MP, Bowers SW, Nichol CA: Biochemical and chemotherapeutic studies of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrmidine (BW 301U): a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 1982, 42:3987-3994.
3. Grant SC, Kris MG, Young CW, Sirontnak FM: Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest 1993, 11:36-45.
4. Degardin M, Domenge C, Cappelaere P, Luboinski B, Navarrete, Scott JE, Lefebvre JI: A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck. Eur J Cancer 1994, 30:1044-1045.
5. Uen WC, Huang AT, Mennel R, Jones SE, Spaulding MB, Killion K, Havlin K, Keegan P, Clendeninn NJ: A phase II study of piritrexim in patients with advanced squamous head and neck cancer. Cancer 1992, 69:1008-1011.
6. Vokes E, Dimery I, Jacobs CD, Karp D, Molina A, Collier MA, Eble ML, Clendeninn NJ: A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. Cancer 1991, 67:2253-2257.
7. van der Laan BF, Jansen G, Kathmann GA, Westerhof GR, Schomagel JH, Hordijk GJ: In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate. Int J Cancer 1992, 51:909-914.
8. Green MD, Sherman P, Zaleberg J: Phase II study of 10-EDAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy. Invest New Drugs 1992, 10:31-34.
9. Schornagel JH, Verweij J, de Mulder PHM, Cognetti F, Vermorken JB, Coppelaere P, Armand JP, Wildiers J, Clavel M, Kirkpatrick A, Lefebvre JL: A phase II trial of 10-ethyl-10 deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 1992, 2:223-226.
10. Schornagel J, Verwey J, de Mulder P, Cognetti F, Vermorken J, Cappaere P, Armand JP, Wildiers J, de Graeff A, Clavel M, Sahmoud T, Kirkpatric A, Lefebvre JL: Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study. J Clin Oncol 1995, 13:1649-1655.
11. Huber M, Dimery IW, Benner S, Lippman S, Shirinian M, Esparaz B, Frenning D, Guillory-Perez C, Hong K: Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck. Invest New Drugs 1994, 12:327-331.
12. Xu YZ, Plunkett W: Modulation of deoxycytidylate deaminase in intact human leukemia cells: action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1992, 245:1819-1827.
13. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Ganhdhi V: Gemcitabine: metabolism, mechanism of action, and self potentiation. Semin Oncol 1995, 11:3-10.
14. Ruiz Van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ: Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cells and solid tumours. Biochem Pharmacol 1994, 48:1327-1339.
15. Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 1991, 51:211-214.
16. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck: EORTC Early Clinical Trials Group. Ann Oncol 1994, 5:543-547.
17. Peters GJ, Bergman AM, Veerman G, Ruiz van Haperen VWT: Synergism between cisplatin (C-Pt) and gemcitabine (dFdC) in resistant A2780 human ovarian cell lines is schedule dependent [abstract]. Proc Am Assoc Cancer Res 1994, 35:328.
18. Steward WP, Dunlop DJ, Cameron C, Tlabot DC, Kleisbauer JP, Thomas P, Guerin JC, Perol M, Sanson C, Dabouis G, Lacroix H: Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995, 14:351.
19. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, DeMarinis F, Salviti F, Cruciani G, Dogliotti L, Cocconi G, Paccagnella A, Adamo V, Incoronato P, Scarcella L, Mosconi AM, Tonato M: Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC): a phase II study [abstract]. Proc Am Soc Clin Oncol 1995, 14:352.
20. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence T: Metabolism of 2′,2′-difluorodeoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994, 54:3219-3223.
21. Burris H, Fields S: Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 1994, 21:14-20.
22. Gebbia V, Testa A, Valeza R, Zerillo G, Restivo S, Ingria F, Cannata G, Gebbia N: A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 1993, 29:1358-1359.
23. Testolin A, Recher G, Cristoferi V, Gasparini G: Vinorelbine (VNB) in pretreated advanced head and neck squamous cell carcinoma: a phase II study. Invest New Drugs 1994, 12:231-234.
24. Gebbia V, Testa A, Di Gregorio C, Ingria F, Valenza R, Cannata G, Moschella F, Restivo G, Gebbia N: Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol 1995, 18:293-296. This study demonstrates a response rate of 55% (15% complete response) in patients with either locally recurrent or metastatic disease. In patients whom were previously untreated, the response rate was 87% (27% complete response).
25. Catimel G, Caliandro R, Terret C, Dumortier B, Gignoux B, Levai J, Montbarbon X, Gourmet R, Droz JP: A phase II study of cisplatin (CDDP) and 96 hours continuous infusion (CI) of Navelbine (NVB) in patients (PTS) with advanced squamous cell carcinoma of the head and neck (HNY) [abstract]. Eur J Cancer 1995, 31A:S94.
26. Gebbia V, Testa A, Valenza R, Ferrero B, Giuffre S, Carreca I, Gebbia N: Vinorelbine plus cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell head and neck carcinoma [abstract]. Proc Am Soc Clin Oncol 1993, 12:283.
27. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfired M, Ruffie P, Panzio A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12:360-367.
28. Gelmon K: The taxoids: paclitaxel and docetaxel. Lancet 1994, 344:1267-1272.
29. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM, Beijnin JH: Taxanes: a new class of antitumor agents. Cancer Invest 1995, 13:381-404.
30. Elomaa L, Joensuu H, Kulmala J, Klemi P, Grenman R: Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol 1995, 115:340-344.
31. Forastiere AA: Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 1993, 20(suppl 3):56-60.
32. Smith RE, Thornton DE, Allen J: A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995, 22:41-46.
33. Lopes NM, Adams EG, Pitts TW, Bhuyan BK: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993, 32:235-242.
34. Jekunen AP, Christen RD, Shalinksy DR, Howell SB: Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994, 69:209-366. An interesting study demonstrating clinical responses with prolonged infusion (96 hours) of paclitaxel in patents who have progression of disease on short infusions (24 hours or less).
35. Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicnet J, Cortes-Funes: Phase I/II study of escalating doses of Taxol + cisplatin with G-CSF (filgrastim) as first-line therapy for head and neck carcinomas: preliminary results [abstract]. Proc Am Soc Clin Oncol 1995, 14:300.
36. Liebmann J, Cook JA, Fisher J, et al.: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994, 86(6):441-446 This trial reports a 73% response rate (seven complete response and six partial response) in patients treated with cisplatin and paclitaxel. Although the number of patients treated in this study is small, further evaluation of this combination is warranted.
37. Posner M, Dreyfus A, Norris C, Costello R, Rossi R, Poulin M, Clark J, Busse P: A phase II trial of docetaxel in squamous cell cancer of the head and neck [abstract]. Eur J Cancer 1995, 31A.
38. Camtimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck (ENG). Ann Oncol 1994, 5:533-537. A response rate of 50% is reported in this small phase II trial. This promising agent merits further study in combination regimens.
39. Fujii H, Sasaki Y, Ebihara S, Kida Y, Ishikawa G, Komiyama S, Inuyama Y: An early phase II study of docetaxel (Taxotere) in patients with head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1995, 14:298.
40. Cervellino JC, Araujo CE, Pirisi C, Francia A, Cerruit R: Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. Oncology 1991, 48:89-92.
41. Kish JA, Tapazoglou E, Ensley J, Al-Sarraf M: Activity of ifosfamide (NSC-109724) in recurrent head and neck cancer patients [abstract]. Proc Am Assoc Cancer Res 1990, 31:190.
42. Domenge C, Schwaab G, Marandas P, Janot F, Luboinski, Gandia D: Phase II feasibility study of ifosfamide/mesna and methotrexate (MTX) in recurrent advanced squamous cell head and neck cancer (SC H+NC) [abstract]. Proc Am Soc Clin Oncol 1994, 13:291.
43. Gupta V, Arena S, Hilal E, Schein G, Torres C, Becker D: High response rate to cisplatin and ifosfamide/mesna in head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994, 13:289.
44. Lemke S, Kellman R, Green D, Chung CT, Young R, Graziano S, Fields SZ: A phase II trial of ifosfamide, cisplatin, oral mesna and ethacrynic acid as an outpatient treatment in advanced squamous cell carcinoma of the head and neck (ASCCHN) [abstract]. Proc Am Soc Clin Oncol 1995, 14:298.
45. Rixe O, Lacoste, Thomas H, et al.: Neoadjuvant chemotherapy (CT) by CDDP (P), 5FU (F), leucovorin (L), and ifosfamide (I) (PLIF) for advanced head and neck (HN) squamous cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1994, 13:290.
46. Forastiere A, Urba S: Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995, 22:24-27.
47. Benner SE, Lippman SM, Huber MH, Hong WK: Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Semin Oncol 1995, 22:22-25.
48. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.: The current status of camptothecin analogues of antitumor agents. J Natl Cancer Inst 1993, 85:271-291.
49. Sinha BK: Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 1995, 49:11-19.
50. Robert F, Wheeler RH, Molthrop DC, et al.: Phase II study of topotecan in advanced head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994, 13:281.
51. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Freidman HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36:393-403.
52. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 1992, 10:839-864.
53. Hong WK, Endicott J, Itri LM, Doos W, Batsakis J, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughn C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S: 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315:1501-1505.
54. Benner SE, Pajak TF, Lippman SM, Earlye C, Hong WK: Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994, 6:140-141.
55. Benner SE, Lippman SM, Hong WK: Retinoids in Head and Neck Cancer. In Retinoids in Oncology. Edited by Hong WK, Lotan R. New York: Marcel Dekker; 1993:203-221.
56. Hemmi H, Breitman TR: Combination of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987, 67:501-507.
57. Dmitrovsky E, Bosl GJ: Active cancer therapy combining 13-cis-retinoic acid with interferon-alpha. J Natl Cancer Inst 1992, 84:218.
58. Smith DC, Jacob HE, Branch RA, et al.: A phase II study of all-trans retinoic acid (ATRA) in advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol 1994, 13:287.
59. Pfister DG, Bajorin D, Motzer RJ, Scher H, Louison C, Harrison L, Shah J, Strong E, Bosl G: A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Invest New Drugs 1993, 11:53-56.
60. Leaf A, Schwartz E, Ritch P: A phase II study of amonifide in carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1994, 13:286.
61. De Mulder PH, Cappelaere P, Cognetti F, Verwij J, Schornagel JH, Vermorken JB, Kirkpatrick A, Lefebve A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma. Cancer Chemother Parmacol 1994, 33:438-440.